BIX 2026 to Spotlight the Future of Stem Cell and Global Biopharma M&A

BIX 2026 unveils keynotes on stem cell advances for nervous system diseases and global biopharma M&A trends, bringing together biotech leaders, investors, and researchers to drive collaboration and innovation.
 
Aug. 14, 2026 - PRLog -- BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), Korea's leading bio and pharmaceutical convention hosted by KoreaBIO and organized by RX, has announced its keynote speakers and opened registration. The event serves as a global business platform connecting biotechnology and pharmaceutical companies, research institutions, investors, and industry stakeholders to explore partnerships and growth opportunities.

This year's keynote program will highlight two major themes shaping the bioindustry: stem cell innovation and global biopharma mergers and acquisitions. On October 28, stem cell and neuroscience expert Dr. Sally Temple will discuss how human stem cell technologies are advancing research, drug discovery, disease modeling, and treatments for nervous system diseases. On October 29, Goodwin's Stuart Cable will provide insights into current biopharma M&A trends, including deal activity, transaction structures, regulatory considerations, and the growing acquisition of innovative biotech companies by pharmaceutical firms.

In addition to the keynotes, BIX 2026 will feature specialized conference sessions, exhibitions, partnering programs, and networking events covering the latest biotechnology innovations, market developments, investment strategies, technology commercialization, and global business expansion. Pre-registration is open until August 31, with early-bird discounts available through the official BIX website.
End
Source: » Follow
Email:***@rxglobal.com
Posted By:***@rxglobal.com Email Verified
Tags:Pharmaceuticals
Industry:Health
Location:Korea, South
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
RX Global PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share